Location: Indianapolis, IndianaWarning Letter Date: September 9, 2025FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)Type of Warning: False & Misleading Claims/Misbranded DrugsSubject of Violation: An Oprah Special: Shame, Blame, and the Weight Loss Revolution, regarding Zepbound (tirzepatide) and Mounjaro (tirzepatide)FDA Warning: In the program, which aired on television in 2024 and until recently was available continuously on the ABC website and through various streaming services, Eli Lilly promoted Mounjaro and Zepbound in a manner that failed to present the serious risks of these drug products in a truthful and nonmisleading manner, despite FDAs prior correspondence (advisory comments dated June 13, 2022 and June 21, 2022)
Rachitskaya and medical student Julia Joo studying an eye on a computer screen Glucagon-like peptide-1 (GLP-1) receptor agonist drugs are gaining popularity as effective glucose-lowering and food-intake-reducing treatment for people with Type 2 diabetes and obesity
Stimulant medications can make some people have a smaller appetite
Chromium, Innoslim and Meratrim collectively work toward a more favorable metabolic environmentwithout direct hormonal triggers seen in GLP-1 therapies
Don't assume anything
